Recognition for heart failure breakthrough
نویسندگان
چکیده
منابع مشابه
Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure.
Recombinant relaxin (serelaxin), a breakthrough therapy for acute heart failure.
متن کاملEmerging Drug Therapies for Heart Failure
Heart failure is associated with high morbidity and mortality and is proving to be an economic burden in developing countries. A number of therapeutic agents are presently employed in heart failure; but they are not sufficient to control symptoms of heart failure. Moreover, the prevalence of chronic heart failure is progressively increasing and thus there is a continuing need to develop effecti...
متن کاملQuantitative Radionuclide Assessment of Cardiac Dyssynchrony: Breakthrough in Patient Selection for Cardiac Resynchronization Therapy for Refractory Heart Failure?
An estimated 5.7 million adults with heart failure (HF) currently burden the human, medical, and financial resources of the United States. By 2030, this number is expected to increase to more than 8 million. In 2012, the total cost of HF in the United States was estimated at $30.7 billion, which is expected to increase to $69.7 billion by 2030. HF contributes substantially to mortality and is d...
متن کاملMetabolic therapy for heart failure including diastolic heart failure
Cardiac energetic impairment is a feature of systolic heart failure irrespective of the underlying etiology, and the magnitude of this impairment is predictive of subsequent mortality. It is also a feature of other forms of heart muscle diseases including hypertrophic cardiomyopathy and heart failure with normal ejection fraction. While the adult heart normally uses predominantly free fatty aci...
متن کاملRevascularization for heart failure.
Coronary artery disease is the most common underlying cause of heart failure, yet there is little consensus on the role of revascularization in the management of patients with ischemic cardiomyopathy. The concept of recovery of dysfunctional but viable myocardium forms the pathophysiologic basis for the benefit of revascularization. Data from observational studies suggest that patients with cor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2021
ISSN: 0195-668X,1522-9645
DOI: 10.1093/eurheartj/ehab321